Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells

Post-Covid pulmonary fibrosis is evident following severe COVID-19. There is an urgent need to identify the cellular and pathophysiological characteristics of chronic lung squeals of Covid-19 for the development of future preventive and/or therapeutic interventions. Tissue-resident memory T (T(RM))...

Descripción completa

Detalles Bibliográficos
Autores principales: Zununi Vahed, Sepideh, Hosseiniyan Khatibi, Seyed Mahdi, Ahmadian, Elham, Ardalan, Mohammadreza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Masson SAS. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8723825/
https://www.ncbi.nlm.nih.gov/pubmed/34995938
http://dx.doi.org/10.1016/j.biopha.2022.112614
Descripción
Sumario:Post-Covid pulmonary fibrosis is evident following severe COVID-19. There is an urgent need to identify the cellular and pathophysiological characteristics of chronic lung squeals of Covid-19 for the development of future preventive and/or therapeutic interventions. Tissue-resident memory T (T(RM)) cells can mediate local immune protection against infections and cancer. Less beneficially, lung T(RM) cells cause chronic airway inflammation and fibrosis by stimulating pathologic inflammation. The effects of Janus kinase (JAK), an inducer pathway of cytokine storm, inhibition on acute Covid-19 cases have been previously evaluated. Here, we propose that Tofacitinib by targeting the CD8(+) T(RM) cells could be a potential candidate for the treatment of chronic lung diseases induced by acute SARS-CoV-2 infection.

Ejemplares similares